The latest research published in Genes & Diseases unveils groundbreaking insights into the role of the aging process and the associated factor EMP1 in the progression of resectable pancreatic cancer ...

Patients with borderline resectable pancreatic cancer (PDAC) are often treated with chemotherapy, radiotherapy, or both before undergoing surgery, but the optimal regimen in this setting is ...

A newly discovered gene switch may help turn chemotherapy-resistant pancreatic cancer into a treatable disease.

Among patients with resectable or borderline resectable pancreatic ductal adenocarcinoma, neoadjuvant FOLFIRINOX showed comparable overall survival to neoadjuvant gemcitabine-based chemoradiotherapy, ...

ExoLuminate: An observational registry study for detection of pancreatic adenocarcinoma (PDAC) in high-risk or clinically suspicious patients. Targeting minimal residual disease (MRD) in resected RAS ...

Ablative radiation therapy led to promising overall survival in patients with technically resectable pancreatic cancer who were high-risk candidates for surgery. The 2-year overall survival rate was ...

A new UCLA investigator-initiated study sponsored by the UCLA Health Jonsson Comprehensive Cancer Center has found that adding immunotherapy to standard chemotherapy before surgery is safe and shows ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147) This study included patients from the investigator-initiated, ...

Scientists have identified a crucial molecular switch that decides whether pancreatic cancer cells resist chemotherapy or respond to it. The key player, a gene called GATA6, keeps tumours in a more ...

REDWOOD CITY, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines (RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today ...